Recent publications have questioned the efficacy of using therapeutic or intermediate doses
of low molecular weight heparin in COVID-19 patients, especially in the most severe
patients. In order to update these recommendations, a non-systematic review has been
carried out in the main medical databases. A total of 14 randomized clinical trials, 14 meta-
analyses and the recommendations of 12 scientific societies were selected, stratified
according to the type of patient (outpatient, hospitalized, admitted to critical care or post …